Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Imagion Biosystems Ltd. ( (AU:IBX) ) has shared an update.
Imagion Biosystems has disclosed a change in director Robert Romeo Proulx’s interests, with the acquisition of 1.4 million ordinary shares and the lapse or disposal of 1.4 million unlisted performance rights tied to market capitalisation milestones. The reshaping of Proulx’s holdings, which now tilt more toward ordinary equity and away from certain performance-based rights, may slightly alter the incentive mix for the director but does not signal a change to the company’s broader operational or clinical strategy.
The most recent analyst rating on (AU:IBX) stock is a Hold with a A$0.02 price target. To see the full list of analyst forecasts on Imagion Biosystems Ltd. stock, see the AU:IBX Stock Forecast page.
More about Imagion Biosystems Ltd.
Imagion Biosystems Limited is a biotechnology company focused on developing diagnostic imaging technologies, including its MagSense platform, for the detection and monitoring of cancers and other diseases. The company’s securities are listed on the ASX, and its capital structure includes ordinary shares, listed options, and a range of unlisted performance options and rights tied to clinical and market-based milestones.
Average Trading Volume: 3,879,403
Technical Sentiment Signal: Hold
Current Market Cap: A$12.64M
See more insights into IBX stock on TipRanks’ Stock Analysis page.